This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the potential use of povorcitinib (INCB54707) for patients with Hidradenitis Suppurativa currently in development by Incyte
Ticker(s): INCYWho's the expert?
Institution: Private Practice
- Manages several patients a week with HS, and those with very severe HS requiring hospitalization about 2 times per month.
Familiar with JAK inhibitors in the pipeline for HS and have seen an article about the Phase II trial for this medication.
Interview Goal Discussing the potential use of povorcitinib (INCB54707) currently in development by Incyte.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
